Literature DB >> 15961356

Detection of Pseudomonas aeruginosa in patients with cystic fibrosis.

G A Tramper-Stranders1, C K van der Ent, T F W Wolfs.   

Abstract

Chronic pulmonary colonisation with Pseudomonas aeruginosa (PA) in patients with CF is associated with a high morbidity and mortality. Adequate treatment of first acquisition of PA might prevent or postpone chronic colonisation. Early detection of PA is therefore of major importance. Currently, cultures of oropharynx or sputum are most commonly practised. However, oropharyngeal culture has limitations both in the positive and negative predictive value for the presence of PA in the lower respiratory tract. Induction of sputum has little benefit in detection of PA. Serology might have additional value in early detection, when bacterial density is too low to be detected by culture. Molecular techniques are not yet widespread used for detection of PA, but have in general a high sensitivity. In this review, we describe the value of different diagnostic techniques for detecting PA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15961356     DOI: 10.1016/j.jcf.2005.05.009

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  15 in total

1.  Pseudomonas serology: confusion, controversy, and challenges.

Authors:  P M Farrell; J R W Govan
Journal:  Thorax       Date:  2006-06-12       Impact factor: 9.139

2.  Diagnostic value of serological tests against Pseudomonas aeruginosa in a large cystic fibrosis population.

Authors:  G A Tramper-Stranders; C K van der Ent; M G Slieker; S W J Terheggen-Lagro; F Teding van Berkhout; J L L Kimpen; T F W Wolfs
Journal:  Thorax       Date:  2006-04-06       Impact factor: 9.139

3.  Assessing Differences in Mortality Rates and Risk Factors Between Hispanic and Non-Hispanic Patients With Cystic Fibrosis in California.

Authors:  MyMy C Buu; Lee M Sanders; Jonathan A Mayo; Carlos E Milla; Paul H Wise
Journal:  Chest       Date:  2016-01-12       Impact factor: 9.410

4.  Proteomic identification of OprL as a seromarker for initial diagnosis of Pseudomonas aeruginosa infection of patients with cystic fibrosis.

Authors:  Aparna R Rao; Anita Laxova; Philip M Farrell; Joseph T Barbieri
Journal:  J Clin Microbiol       Date:  2009-06-24       Impact factor: 5.948

5.  Early Respiratory Bacterial Detection and Antistaphylococcal Antibiotic Prophylaxis in Young Children with Cystic Fibrosis.

Authors:  Matthew N Hurley; Andrew Fogarty; Tricia M McKeever; Christopher H Goss; Margaret Rosenfeld; Alan R Smyth
Journal:  Ann Am Thorac Soc       Date:  2018-01

6.  Pseudomonas aeruginosa serological analysis in young children with cystic fibrosis diagnosed through newborn screening.

Authors:  D Hayes; P M Farrell; Z Li; S E West
Journal:  Pediatr Pulmonol       Date:  2010-01

7.  Assessment of IgG antibodies to Pseudomonas aeruginosa in patients with cystic fibrosis by an enzyme-linked immunosorbent assay (ELISA).

Authors:  Renan Marrichi Mauch; Cláudio Lúcio Rossi; José Dirceu Ribeiro; Antônio Fernando Ribeiro; Marcos Tadeu Nolasco da Silva; Carlos Emílio Levy
Journal:  Diagn Pathol       Date:  2014-08-22       Impact factor: 2.644

8.  Assessment of serology and spirometry and the combination of both to complement microbiological isolation for earlier detection of Pseudomonas aeruginosa infection in children with cystic fibrosis.

Authors:  Ana Kotnik Pirš; Uroš Krivec; Saša Simčič; Katja Seme
Journal:  BMC Pulm Med       Date:  2016-11-25       Impact factor: 3.317

9.  Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate "normative adherence".

Authors:  Zhe Hui Hoo; Rachael Curley; Michael J Campbell; Stephen J Walters; Daniel Hind; Martin J Wildman
Journal:  Patient Prefer Adherence       Date:  2016-05-23       Impact factor: 2.711

10.  Detection of hydrogen cyanide from oral anaerobes by cavity ring down spectroscopy.

Authors:  Wen Chen; Kajsa Roslund; Christopher L Fogarty; Pirkko J Pussinen; Lauri Halonen; Per-Henrik Groop; Markus Metsälä; Markku Lehto
Journal:  Sci Rep       Date:  2016-03-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.